[1] The current standard of care for mild to moderate AD involves treatment with acetylcholinesterase inhibitors to improve cognitive function. The N-methyl-d-aspartate antagonist memantine has also been reported to improve cognitive function in patients with moderate to severe AD. [2] While these drugs improve the symptoms of AD, they do not have substantial disease-modifying effects. [3] Thus, attempts have been made to identify individuals at increased risk of AD, and to test interventions that might delay the progression of prodromal symptoms of dementia. The gene discussed is ACHE; the disease is Alzheimer disease.